Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
T Cell Non-Hodgkin Lymphoma: early-phase trial registry
1 of 6 indexed T Cell Non-Hodgkin Lymphoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,866 of 28,707 conditions by registered trial count.
6 US clinical trials · 1 currently recruiting · #2,866 of 28,707 conditions by registered trial count
T Cell Non-Hodgkin Lymphoma: 6 US clinical trials tracked, 1 recruiting.
T Cell Non-Hodgkin Lymphoma is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), running 1 of these trials.
Enrollment posture brief
Registry condition t-cell-non-hodgkin-lymphoma
OPEN 1 | RECR 17% | LATE 0 | EARLY 6 | RANK #2866 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Acute Renal Failure (17% recruiting · 6 trials)
T Cell Non-Hodgkin Lymphoma lists 1 open slots (17% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for T Cell Non-Hodgkin Lymphoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
T Cell Non-Hodgkin Lymphoma is recruiting below its size-band peers.
1 of 6 indexed trials (16.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates T Cell Non-Hodgkin Lymphoma research.
VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) accounts for 1 of 6 trials (16.7%). 6 distinct sponsors appear on at least one study for this condition label.
-
Most T Cell Non-Hodgkin Lymphoma trials plan to enrol fewer than 100 people.
Median target enrolment is 47 among the 6 trials that report a genuine target (sentinel values excluded). 6 of those (100%) plan for fewer than 100 participants.
-
T Cell Non-Hodgkin Lymphoma research is mostly interventional.
6 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
6 total, page 1 of 1
CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)
Vittoria Biotherapeutics
NCT06420089
Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies
Washington University School of Medicine
NCT05377827
A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)
VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
NCT03833180
Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant
M.D. Anderson Cancer Center
NCT00880815
A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
NCT01908777
CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma
Robert Lowsky
NCT02424968
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on T Cell Non-Hodgkin Lymphoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on T Cell Non-Hodgkin Lymphoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this T Cell Non-Hodgkin Lymphoma page
6 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 T Cell Non-Hodgkin Lymphoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) sponsors the most T Cell Non-Hodgkin Lymphoma trials on record, review their full trial history before evaluating a specific study. See VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This T Cell Non-Hodgkin Lymphoma condition card totals 6 registered trials; most-linked intervention Anti-Thymocyte Globulin; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.